logo
Share SHARE
FONT-SIZE Plus   Neg

Vanda Pharma Acquires Rights To NK-1 Receptor Antagonist From Eli Lilly

Vanda Pharmaceuticals Inc. (VNDA) said it has acquired an exclusive world-wide license from Eli Lilly and Co. (LLY) to develop and commercialize a small molecule neurokinin 1 receptor, or NK-1R, antagonist for all human indications.

As per the terms of the agreement with Eli Lilly, Vanda Pharma will pay an initial license fee of $1 million and will be responsible for all development costs. Eli Lilly is also eligible to get extra payments on the basis of achievement of specified development and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. These milestones include $4 million for pre-NDA approval milestones and up to $95 million for future regulatory approval and sales milestones.

Vanda Pharma stated that in 2012, it plans to initiate and complete the technology transfer activities and further examine the clinical and commercial profile of VLY-686. This strategic evaluation will further inform potential indications for an early development clinical program, noted the company.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Food delivery startup DoorDash and courier service Postmates have joined with robotic delivery developer Starship Technologies for conducting commercial delivery trials over the next few weeks. With Starship's self-driving delivery robots, DoorDash will do the delivery tests in Redwood City, California, while Postmates' tests will take place in Washington, D.C. They will carry food orders ... Aiming to better prepare its employees, Delta Air Lines has decided to begin new diversity training for all of its flight crews after incidents of alleged discrimination against passengers, Bloomberg reported. *** is the stock in focus, on the merit of its valuation and upbeat guidance revision. The company ***, a vendor of fiber-optic components, revised up fourth-quarter revenue guidance above Street estimates. We think the stock has at least 10% upside from current levels.
comments powered by Disqus
RELATED NEWS
Trade VNDA now with 
Follow RTT